Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display

2149 - Treatment inferred from mutations identified using massive parallel sequencing leads to clinical benefit in some heavily pretreated cancer patients


10 Oct 2016


Poster display


Aviad Zick


Annals of Oncology (2016) 27 (6): 15-42. 10.1093/annonc/mdw363


A. Zick1, T. Peretz1, M. Lotem2, A. Hubert2, D. Katz2, M. Temper2, Y. Rottenberg2, B. Uziely2, H. Nechushtan2, A. Meirovitz2, A. Sonnenblick2, E. Sapir2, D. Edelman2, Y. Goldberg2, A. Lossos3, S. Rosenberg3, I. Fried4, R. Finklstein5, E. Pikarsky5, H. Goldshmidt5

Author affiliations

  • 1 Oncology, Hadassah Ein Kerem, 91120 - Jerusalem/IL
  • 2 Oncology, Hadassah Ein Kerem, Jerusalem/IL
  • 3 Neuro-oncology, Hadassah Ein Kerem, Jerusalem/IL
  • 4 Pediatrics, Hadassah Ein Kerem, Jerusalem/IL
  • 5 Pathology, Hadassah Ein Kerem, Jerusalem/IL


Abstract 2149


Molecular portraits of numerous tumors have flooded oncologists with vast amounts of data. In parallel, effective inhibitors of central pathways have shown great clinical benefit. Together, this promises potential clinical benefit to otherwise end-stage cancer patients.


Here, we report a clinical service offering mutation detection of archived samples using the ion Ampliseq™ cancer panel coupled with clinical consultation. A multidisciplinary think tank consisting of cancer-biologists, genetic counselors, oncologists, and pathologists discussed 67 patient cases, taking into account the identified mutations, the case history and relevant literature.


The team generated a treatment plan, targeting specific mutations, for 41 out of 64 cases. Three patients died before results were available. For 32 patients, the treating oncologists chose not to include the panel recommendation in the treatment plan for various reasons. Nine patients were treated as recommended by the panel, five with clinical benefit and four with disease progression.


This study suggests that routine use of massive parallel tumor sequencing is feasible and can judiciously affect treatment decisions when coupled with multidisciplinary team-based decision making. Administration of personally based therapies at an earlier stage of therapy, expansion of genetic alterations examined and increased availability of biological therapies may lead to further improvement in the clinical outcome of patients.

Clinical trial identification

Legal entity responsible for the study

Hadassah Medical Organization


Hadassah Medical Center


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings